<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03873038</url>
  </required_header>
  <id_info>
    <org_study_id>2060-004</org_study_id>
    <secondary_id>MK-2060-004</secondary_id>
    <nct_id>NCT03873038</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)</brief_title>
  <official_title>Single and Multiple Dose Clinical Trial to Study the Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple&#xD;
      doses in older adult participants with end-stage renal disease (ESRD) on hemodialysis (HD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 29, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Any Adverse Event (AE)</measure>
    <time_frame>Part 1: Up to ~5 months after last study dose; Part 2: Up to ~3 months after last dose</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Any Serious Adverse Event</measure>
    <time_frame>Part 1: Up to ~5 months after last study dose; Part 2: Up to ~3 months after last dose</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Systemic AE</measure>
    <time_frame>Part 1: Up to ~5 months after last study dose; Part 2: Up to ~3 months after last dose</time_frame>
    <description>Systemic AEs reported by participants in one or more treatment arms will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Injection-Site AE</measure>
    <time_frame>Part 1: Up to ~5 months after last study dose; Part 2: Up to ~3 months after last dose</time_frame>
    <description>Injection-site AEs reported by participants in one or more treatment arms will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study due to an AE</measure>
    <time_frame>Part 1: Up to ~5 months after last study dose; Part 2: Up to ~3 months after last dose</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 from 0 to Infinity (AUC0-inf)</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and AUC0-inf will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Plasma Concentration-Time Curve of MK-2060 from Time 0 to 168 Hours (AUC0-168)</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and AUC0-168 hours will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Observed Plasma Concentration (Cmax) of MK-2060</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and Cmax will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Plasma Concentration of MK-2060 at 168 Hours (C168)</measure>
    <time_frame>168 hours post dose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and C168 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to Maximum Observed Plasma Drug Concentration (Tmax) of MK-2060</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and Tmax will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC0-168 of MK-2060</measure>
    <time_frame>Up to ~118 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and AUC0-168 hours will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax of MK-2060</measure>
    <time_frame>Up to ~118 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and Cmax will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: C168 of MK-2060</measure>
    <time_frame>168 hours post dose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and C168 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Tmax of MK-2060</measure>
    <time_frame>Up to ~118 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and Tmax will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Elimination Terminal Half-life (t ½) of MK-2060</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and t ½ will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Clearance (CL) of MK-2060</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and CL will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Volume of Distribution (Vz) of MK-2060</measure>
    <time_frame>At designated time points on Day 1 and up to ~157 days postdose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and Vz will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Activated Partial Thromboplastin Time (aPTT) of MK-2060</measure>
    <time_frame>Baseline and 168 hours post-dose</time_frame>
    <description>Plasma samples will be collected at pre-specified time points post-dose and aPTT values will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Renal Dialysis</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Part 1, Panel A: MK-2060 (8 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 8-mg dose of MK-2060 via intravenous (IV) infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Panel B: MK-2060 (20 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 20-mg dose of MK-2060 via IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Panel C: MK-2060 (40 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 40-mg dose of MK-2060 via IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: MK-2060 (25 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three doses of up to 25 mg MK-2060 via IV infusion in the first week (Week 1), followed by a single dose of up to 25 mg MK-2060 via IV infusion weekly for 3 weeks (Weeks 2-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 (Panels A, B, C) and Part 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Participants will receive a single dose of placebo via IV infusion. Part 2: Participants will receive three doses of placebo via IV infusion in the first week and then a single dose of placebo via infusion weekly for 3 weeks (Weeks 2-4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-2060</intervention_name>
    <description>Part 1: Single doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion on Day 1.&#xD;
Part 2: Three doses of 25 mg of MK- 2060 administered via IV infusion on Days 1, 3 and 5; Followed by single doses of 25 mg of MK-2060 administered via IV infusion on Days 8, 15, and 22.</description>
    <arm_group_label>Part 1, Panel A: MK-2060 (8 mg)</arm_group_label>
    <arm_group_label>Part 1, Panel B: MK-2060 (20 mg)</arm_group_label>
    <arm_group_label>Part 1, Panel C: MK-2060 (40 mg)</arm_group_label>
    <arm_group_label>Part 2: MK-2060 (25 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part 1: Single dose of placebo will be administered via IV infusion on Day 1. Part 2: Three doses of placebo administered via IV infusion on Days 1, 3 and 5; Followed by single doses of placebo administered via IV infusion on Days 8, 15, and 22.</description>
    <arm_group_label>Part 1 (Panels A, B, C) and Part 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, of non-child bearing potential (WONCBP) age ≥40 and ≤80 years for Part&#xD;
             1 and ≥18 and ≤80 years for Part 2.&#xD;
&#xD;
          -  End-stage renal disease (ESRD) maintained on stable outpatient hemodialysis (HD)&#xD;
             regimen, using an established (&gt; 3 months) and normally functioning, regular flow,&#xD;
             uninfected mature arteriovenous (AV) fistula or AV graft and skin consistent with&#xD;
             standard chronic HD access injuries, and HD stability defined as ([K, dialyzer&#xD;
             clearance, multiplied by t, time, divided by V, patient's total body water] Kt/V) ≥&#xD;
             1.2 within 3 months prior to dosing at a healthcare center for &gt; 3 months from dosing.&#xD;
&#xD;
          -  On HD regimen at least 3 times per week for a minimum of 3 hours per dialysis session,&#xD;
             using a complication-free well-maintained AV fistula or AV graft, expected and plan to&#xD;
             continue this throughout and for at least 3 months beyond the study.&#xD;
&#xD;
          -  Has a Body Mass Index (BMI) ≥ 18 and ≤ 45 kg/m^2, BMI = weight (kg)/height (m)^2.&#xD;
&#xD;
          -  Baseline health is judged to be stable based on medical history, physical examination,&#xD;
             vital sign measurements and electrocardiogram (ECG) performed prior to randomization.&#xD;
&#xD;
          -  Liver function test (serum alanine aminotransferase [ALT] and aspartate&#xD;
             aminotransferase [AST]) must be equal to or below 1.5X upper limit of normal (ULN) and&#xD;
             deemed not clinically significant by both the investigator and the Sponsor.&#xD;
&#xD;
          -  Contraceptive use by men should be consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies by agreeing to&#xD;
             use a male condom plus partner use of an additional contraceptive method when having&#xD;
             penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not&#xD;
             currently pregnant. Also, men with a pregnant or breastfeeding partner must agree to&#xD;
             remain abstinent from penile-vaginal intercourse or use a male condom during each&#xD;
             episode of penile-vaginal penetration.&#xD;
&#xD;
          -  Contraceptive use by women should be consistent with local regulations regarding the&#xD;
             methods of contraception for those participating in clinical studies in that a female&#xD;
             participant is eligible to participate if she is not pregnant or breastfeeding and she&#xD;
             is not a WOCBP in that she is a postmenopausal female without menses for at least 1&#xD;
             year OR is a surgically sterile female, post hysterectomy, bilateral salpingectomy,&#xD;
             oophorectomy or tubal ligation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of any clinically significant concomitant disease or condition&#xD;
             (including treatment for such conditions) or diseases whose current condition is&#xD;
             considered clinically unstable that, in the opinion of the investigator, could either&#xD;
             interfere with the study drug, compromise interpretation of study data, or pose an&#xD;
             unacceptable risk. Participants with a remote history of uncomplicated medical events&#xD;
             (e.g., uncomplicated kidney stones, as defined as spontaneous passage and no&#xD;
             recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at&#xD;
             the discretion of the investigator.&#xD;
&#xD;
          -  Is mentally or legally incapacitated, has significant emotional problems at the time&#xD;
             of prestudy (screening) visit or expected during the conduct of the study or has a&#xD;
             history of clinically significant psychiatric disorder of the last 5 years.&#xD;
             Participants who have had situational depression may be enrolled in the study at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
          -  Has a history of cancer (malignancy), including adenocarcinoma, with possible&#xD;
             exceptions being participants with adequately treated non-melanomatous skin carcinoma;&#xD;
             participants with other malignancies which have been successfully treated ≥10 years&#xD;
             prior to the pretrial (screening) visit; or participants who, in the opinion of the&#xD;
             trial investigator, are highly unlikely to sustain a recurrence for the duration of&#xD;
             the trial.&#xD;
&#xD;
          -  Has blood coagulation test (activated partial thromboplastin time [aPTT], prothrombin&#xD;
             time [PT]) ≥ 20 % outside of normal range on pretrial (screening), which are&#xD;
             considered clinically significant by both the investigator and the sponsor.&#xD;
&#xD;
          -  Any other clinically significant abnormalities in laboratory test results at screening&#xD;
             that would, in the opinion of the investigator, increase the participant's risk of&#xD;
             participation, jeopardize complete participation in the study, or compromise&#xD;
             interpretation of study data.&#xD;
&#xD;
          -  Has a history of deep vein thrombosis or pulmonary embolism. Has a history of vascular&#xD;
             access thrombosis within 1 month prior to enrollment. Has a personal or family history&#xD;
             of bleeding disorder.&#xD;
&#xD;
          -  Has a history of gastrointestinal (GI) bleeding, duodenal polyps or gastric ulcer in&#xD;
             the last 5 years or severe hemorrhoidal bleed in last 3 months.&#xD;
&#xD;
          -  Has a history of or current frequent epistaxis within the last 3 months or active&#xD;
             gingivitis.&#xD;
&#xD;
          -  Has ongoing anticoagulant therapy (warfarin, apixaban, dabigatran, rivaroxaban,&#xD;
             edoxaban, betrixaban) or antiplatelet therapy (clopidogrel, prasugrel, ticagrelor,&#xD;
             ticlopidine). Intradialytic heparin and aspirin are permitted.&#xD;
&#xD;
          -  At the time of screening or pre-dose, has planned significant dental procedures&#xD;
             (including planned dental surgery), or other planned surgical procedures within&#xD;
             duration of participation in the trial.&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen or human immunodeficiency viruses (HIV).&#xD;
&#xD;
          -  Has had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4&#xD;
             weeks prior to the pre-study (screening) visits.&#xD;
&#xD;
          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex&#xD;
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.&#xD;
             systemic allergic reaction) to prescription or non-prescription drugs or food.&#xD;
&#xD;
          -  Has a tattoo, scar, or other physical finding at the area of the infusion site that&#xD;
             would interfere with infusion or a local tolerability assessment.&#xD;
&#xD;
          -  Has a history of receiving any human immunoglobulin preparation such as intravenous&#xD;
             immunoglobulin (IVIG) or RhoGAM within the last year.&#xD;
&#xD;
          -  Has a history of receiving any biological therapy (including human blood products or&#xD;
             monoclonal antibodies; excluding erythropoietin and insulin) within the last 3 months&#xD;
             or 5 half-lives (whichever is longer), or vaccination within the last 1 month&#xD;
             (exceptions include seasonal flu vaccine and pneumococcal vaccine within the last&#xD;
             month; coronavirus disease 2019 [COVID-19] vaccine that is licensed and approved for&#xD;
             emergency use and with the study intervention given 72 hours following vaccination or&#xD;
             48 hours prior to vaccination).&#xD;
&#xD;
          -  The exclusion criteria for ECG is a heart rate &lt; 40 or &gt; 110 beats per minute (bpm);&#xD;
             corrected Q-T (QTc) interval &gt; 500 minutes/second; any significant arrhythmia or&#xD;
             conduction abnormality, (including but not specific to atrioventricular block [2nd&#xD;
             degree or higher], Wolff Parkinson White syndrome [unless curative radio ablation&#xD;
             therapy]), which, in the opinion of the investigator and sponsor, could interfere with&#xD;
             the safety for the individual participant; and non-sustained or sustained ventricular&#xD;
             tachycardia (&gt; 2 consecutive ventricular ectopic beats at a rate of &gt; 1.7/second).&#xD;
&#xD;
          -  Is unable to refrain from or anticipates the use of medication, including prescription&#xD;
             and nonprescription drugs or herbal remedies beginning approximately 2 weeks prior to&#xD;
             administration of the initial dose of study drug, throughout the study until the&#xD;
             poststudy visit. Specific allowed and prohibited medications are provided in the&#xD;
             protocol.&#xD;
&#xD;
          -  Has participated in another investigational study within 4 weeks prior to sponsor's&#xD;
             investigational drug (MK-2060/placebo) administration.&#xD;
&#xD;
          -  Has a blood pressure &gt;190 mmHg systolic or &gt;110 mmHg diastolic.&#xD;
&#xD;
          -  Consumes greater than 3 glasses of alcoholic beverages (1 glass is approximately&#xD;
             equivalent to: beer 354 mL/12 ounces, wine 118 mL/4 ounces, or distilled spirits 29.5&#xD;
             mL/1 ounce) per day. Participants who consume 4 glasses of alcoholic beverages per day&#xD;
             may be enrolled at the discretion of the investigator.&#xD;
&#xD;
          -  Consumes excessive amounts, defined as greater than 6 servings (1 serving is&#xD;
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks,&#xD;
             or other caffeinated beverages per day.&#xD;
&#xD;
          -  Is a regular user of any illicit drugs or has a history of drug (including alcohol)&#xD;
             abuse within approximately 2 years. Participants must have a negative serum or saliva&#xD;
             drug screen prior to randomization. Participants with a positive drug screen due to&#xD;
             the use of physician prescribed medications (e.g., opioids, benzodiazepines,&#xD;
             antidepressants) may be enrolled at the discretion of the investigator. In addition,&#xD;
             participants with a positive tetrahydrocannabinol (THC) may be enrolled at the&#xD;
             discretion of the investigator if the participants' THC use is under 4 times/month and&#xD;
             the participants agree to not use during their study participation. Participants with&#xD;
             positive THC on screening may have rechecks performed at the discretion of the&#xD;
             investigator to ensure compliance with abstinence from THC use during study&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center ( Site 0002)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research ( Site 0003)</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research ( Site 0001)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

